Rational Therapy of Familial Hypercholesterolemia
Gary A. Reynolds, MD H eterozygous familial hypercholesterolemia (FH) is a common genetic disorder that places one in 500 individuals at risk for premature coronary artery disease, and it is found in 5% of patients who have had a myocardial infarction under age 60.1 Patients with this syndrome usually have elevated levels of low-density lipoprotein (LDL) cholesterol that are twofold to threefold above normal levels. On physical examination, tendon xanthomas are a common and specific manifestation. Palpebral, tuberous, and subperiosteal xanthomas are also common, as is arcus cornae. Family history reveals autosomal dominant inheritance. Studies by Goldstein and Brown2'3 have shown that individuals with this disorder possess one normal and one abnormal allele for the LDL receptor, which is the cell surface receptor responsible for the clearance of LDL from plasma by receptor-mediated endocytosis. Multiple mutations at the LDL receptor locus have been described in humans. 4 Studies of the pathogenesis of FH have been facilitated by the existence of an animal model for the disease in the form of the Watanabe Heritable Hyperlipidemic (WHHL) rabbit. The LDL receptor defect in these animals has also been characterized at the molecular level. 5, 6 In this issue of Circulation, Kume et a17 have used the WHHL rabbit model to See p 1084 examine the effects of pharmacologic intervention with a new class of cholesterol-lowering drugs, the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase. Their work adds to the accumulated data indicating that these drugs act by increasing the transcription of the LDL receptor gene, thus allowing the normal gene to compensate for the mutant gene in heterozygotes with FH.
Evidence that identification and treatment of patients with hypercholesterolemia will slow the development and progression of atherosclerosis has Metabolic balance studies have shown that the elevation of plasma cholesterol in patients with heterozygous FH is due both to diminished clearance of LDL from plasma and increased production of LDL.l0,11 Studies with homozygous WHHL rabbits suggest that the latter defect results from diminished uptake of intermediate-density lipoprotein (IDL, the precursor for LDL) by the liver, with subsequent increased conversion of IDL to LDL.5 IDL contains both apolipoprotein E and apolipoprotein B-100 and is avidly bound by the LDL receptor, so the same receptor appears to mediate the uptake of both lipoproteins. Therefore, it is apparent that interventions that stimulate the production of functional LDL receptors by the liver would tend to correct both of the disturbed mechanisms responsible for maintenance of elevated cholesterol levels in these patients. Two classes of drugs that appear to be particularly promising in this regard include the bile acid sequestrants and the more recently developed HMG CoA reductase inhibitors.
Bile acid sequestrants work by binding and preventing the resorption of bile acids in the lumen of the gut.12 This results in the increased conversion of cholesterol to bile acids by the liver. Metabolic studies of patients with heterozygous FH suggest that as a consequence of this relative intrahepatic cholesterol depletion there is an increased clearance of LDL from plasma by what appears to be an LDL receptor-dependent mechanism.13 This is consistent with studies in dogs treated with bile acid sequestrants that show increased LDL receptors in liver tissue.14 HMG CoA reductase inhibitors are potent cholesterol-lowering drugs that diminish the enzymatic conversion of HMG CoA to mevalonate, the rate-limiting step in endogenous cholesterol production. Depletion of intracellular cholesterol stores by these agents results in the increased expression of LDL receptors by the liver as has been inferred from metabolic balance studies in patients with heterozygous FH15 and in LDL receptor expression studies in dogs14 and hamsters.' 6 Kume et a17 studied the effects of the HMG CoA reductase inhibitor CS-514 (pravastatin) alone, and in combination with cholestyramine, on plasma cholesterol levels and LDL receptor expression in heterozygous WHHL rabbits. The investigators show an additive effect of these two drugs on lowering serum cholesterol and show that this correlates with an additive effect on stimulation of LDL receptor expression in the liver as judged by a membrane-binding assay. These observations support the conclusions drawn from metabolic balance studies in humans with heterozygous FH that increased LDL receptor expression in the liver is an important and desirable mechanism by which these drugs lower cholesterol.l5 Stimulation of LDL receptor protein expression correlates with the induction of both normal and mutant mRNA, which is consistent with previous observations in hamsters and homozygous WHHL rabbits. '6 The recent FDA approval of the HMG CoA reductase inhibitor lovastatin as a therapeutic option in the treatment of patients with primary hypercholesterolemia (Types lla and lIb) that is not responsive to dietary therapy has added a powerful cholesterol-lowering tool for the management of these patients. The principal advantages of this drug are its ability to dramatically reduce cholesterol in a dose-dependent fashion and its favorable side effect profile. '7,18 Lovastatin given in recommended doses appears to be a relatively safe drug, although enzymatic evidence of liver dysfunction can occur, an effect that is common to many hypolipidemic agents. 19 Myositis has also been reported.20 Concerns about tumorigenesis with HMG CoA reductase inhibitors have been expressed, but at recommended doses, this effect has not been seen thus far with lovastatin.'9 Other reductase inhibitors, such as the drug CS-514 that was used in the study by Kume et a17 in this issue of Circulation, are currently under development. Of note, it is currently a matter of debate whether CS-514 is more liver-specific than lovastatin. 21 Several factors need to be weighed by the physician making therapeutic choices for the patient with hypercholesterolemia who is not responsive to dietary therapy. As previously mentioned, longterm experience has been accumulated with several agents to show that cholesterol reduction in patients with hypercholesterolemia lessens cardiovascular morbidity in both symptomatic and asymptomatic patients. The agents that have been used in these studies include bile acid sequestrants, gemfibrozil, clofibrate, and nicotinic acid.9 Evidence of increased noncardiac death rate while on clofibrate therapy has raised concerns about its use.9 Side effects can limit patient compliance with all of these agents but are a particular problem for nicotinic acid.22'23 The cholesterol reduction achievable with gemfibrozil is modest and somewhat variable depending on the patient's lipoprotein profile.24 The addition of lov-astatin as a potent cholesterol-lowering agent with limited side effects therefore represents a welcome addition to the therapy of hypercholesterolemia. Long-term studies will be required to conclusively show that therapy with an HMG CoA reductase inhibitor has beneficial effects on cardiovascular morbidity and mortality.
The patient with heterozygous FH would at present appear to be an ideal candidate for therapy with an HMG CoA reductase inhibitor. Major cholesterol reduction is often necessary to bring cholesterol levels within the desirable range in these patients, and lovastatin provides a therapeutic intervention capable of approaching this goal, although the addition of a bile acid sequestrant is usually necessary to bring cholesterol into the desirable range.15 This therapeutic regimen has been shown to address both of the mechanisms by which elevated cholesterol levels occur in this disease both by increasing the clearance of LDL from plasma and by decreasing its synthesis. 25 The ability of an HMG CoA reductase inhibitor, especially when combined with a bile acid sequestrant, to induce LDL receptor expression and to lower plasma cholesterol suggests that this regimen may also be an attractive combination for other types of hypercholesterolemia that are genetically less well defined but for which inappropriately depressed expression of functionally normal LDL receptors may play a role. Many patients with primary moderate hypercholesterolemia fall into this category, and they experience marked cholesterol reductions with this regimen. 26 Patients with familial combined hyperlipidemia, many of whom have elevated LDL levels because of very low-density lipoprotein overproduction, may also benefit from the addition of an HMG CoA reductase inhibitor to their therapeutic regimen.27 Individuals with uncommon genetic abnormalities of the apolipoproteins of LDL, such as familial type 3 hyperlipoproteinemia (abnormal apoE2), may also benefit by therapy with these agents. 28 Hence, a large percentage of patients with hypercholesterolemia may benefit from the development of these new drugs, improved understanding of their mechanisms of action, and the clinical studies in patients with FH.
